We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LBCL

News List

Japan approves Bristol Myers Squibb’s B-cell lymphoma therapy pharmaceutical-business-review
March 31, 2021
Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or refractory (R/R) large B-cell lymphoma (LBCL) and R/R ...
FDA Approves BMS CAR-T Cell Therapy contractpharma
February 10, 2021
Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma.
Gilead’s CAR T therapy Yescarta shows potential in new indication pharmatimes
December 10, 2020
Gilead’s Yescarta has scored some promising interim results from a phase II study evaluating the chimeric antigen receptor (CAR) T therapy as a first-line treatment for high-risk large B-cell lymphoma (LBCL) patients.